200 related articles for article (PubMed ID: 17341420)
1. A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease.
Liebetanz D; Baier PC; Paulus W; Meuer K; Bähr M; Weishaupt JH
Exp Neurol; 2007 May; 205(1):207-13. PubMed ID: 17341420
[TBL] [Abstract][Full Text] [Related]
2. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
3. Effects of commissural de- and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis.
Liebetanz D; Merkler D
Exp Neurol; 2006 Nov; 202(1):217-24. PubMed ID: 16857191
[TBL] [Abstract][Full Text] [Related]
4. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
5. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Kim ST; Son HJ; Choi JH; Ji IJ; Hwang O
Brain Res; 2010 Jan; 1306():176-83. PubMed ID: 19804765
[TBL] [Abstract][Full Text] [Related]
6. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
[TBL] [Abstract][Full Text] [Related]
7. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
8. Vigilance states in a parkinsonian model, the MPTP mouse.
Monaca C; Laloux C; Jacquesson JM; Gelé P; Maréchal X; Bordet R; Destée A; Derambure P
Eur J Neurosci; 2004 Nov; 20(9):2474-8. PubMed ID: 15525288
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of Parkinson's disease.
Song S; Sava V; Rowe A; Li K; Cao C; Mori T; Sanchez-Ramos J
Neurosci Lett; 2011 Jan; 487(2):153-7. PubMed ID: 20951187
[TBL] [Abstract][Full Text] [Related]
10. Acoustic startle response, prepulse inhibition, and spontaneous locomotor activity in MPTP-treated mice.
Leng A; Yee BK; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):449-56. PubMed ID: 15313033
[TBL] [Abstract][Full Text] [Related]
11. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
[TBL] [Abstract][Full Text] [Related]
12. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P
Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Nicholas AP
Mov Disord; 2007 Jan; 22(1):99-104. PubMed ID: 17133519
[TBL] [Abstract][Full Text] [Related]
14. A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
Quinn LP; Perren MJ; Brackenborough KT; Woodhams PL; Vidgeon-Hart M; Chapman H; Pangalos MN; Upton N; Virley DJ
J Neurosci Methods; 2007 Aug; 164(1):43-9. PubMed ID: 17498809
[TBL] [Abstract][Full Text] [Related]
15. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
Willis GL; Robertson AD
Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376
[TBL] [Abstract][Full Text] [Related]
16. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease.
Przedborski S; Vila M
Ann N Y Acad Sci; 2003 Jun; 991():189-98. PubMed ID: 12846987
[TBL] [Abstract][Full Text] [Related]
17. Protocol for the MPTP mouse model of Parkinson's disease.
Jackson-Lewis V; Przedborski S
Nat Protoc; 2007; 2(1):141-51. PubMed ID: 17401348
[TBL] [Abstract][Full Text] [Related]
18. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
[TBL] [Abstract][Full Text] [Related]
19. Alteration in the differentiation-related molecular expression in the subventricular zone in a mouse model of Parkinson's disease.
Oizumi H; Hayashita-Kinoh H; Hayakawa H; Arai H; Furuya T; Ren YR; Yasuda T; Seki T; Mizuno Y; Mochizuki H
Neurosci Res; 2008 Jan; 60(1):15-21. PubMed ID: 17963913
[TBL] [Abstract][Full Text] [Related]
20. Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task.
Campos-Romo A; Ojeda-Flores R; Moreno-Briseño P; Fernandez-Ruiz J
J Neurosci Methods; 2009 Mar; 177(2):361-8. PubMed ID: 19022292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
